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ABSTRACT: A reversed-phase high-performance liquid chromatographic (HPLC) method has been developed and validated for
the determination of insulin in nanoparticulate dosage forms. Its application for the development and characterization of insulin-
loaded nanoparticulates composed of polyelectrolytes has also been carried out. A reversed-phase (RP) C18 column and gradient
elution with a mobile phase composed of acetonitrile (ACN) and 0.1% aqueous trifluoroacetic acid (TFA) solution at a flow rate
of 1 mL/min was used. Protein identification was made by UV detection at 214 nm. The gradient changed from 30:70 (ACN:TFA,
v/v) to 40:60 (v/v) in 5 min followed by isocratic elution at 40:60 (v/v) for a further five minutes. The method was linear in the
range of 1–100 µg/mL (R2 = 0.9996), specific with a good inter-day and intra-day precision based on relative standard deviation
values (less than 3.80%). The recovery was between 98.86 and 100.88% and the detection and quantitation limits were 0.24 and
0.72 µg/mL, respectively. The method was further tested for the determination of the association efficiency of insulin to
nanoparticulate carriers composed of alginate and chitosan, as well as its loading capacity for this protein. Encapsulant release un-
der simulated gastrointestinal fluids was evaluated. The method can be used for development and characterization of insulin-
loaded nanoparticles made from cross-linked chitosan-alginate. Copyright © 2006 John Wiley & Sons, Ltd.
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production is not enough to ensure daily needs of this
hormone. It is a well characterized protein with a
molecular weight of 5.8 kDa and composed of two
peptide chains, referred to as the A-chain of 21 amino
acid residues and the B-chain of 30 amino acid
residues. Two disulfide bridges link these chains
together and another intrapeptide disulfide bond exists
in the A-chain (Brange et al., 1997).
The desire of a more convenient and socially com-
patible route of insulin administration other than sub-
cutaneous injection has originated several approaches
to attempt its oral delivery. The association of insulin
with colloidal drug carriers which might be able to pro-
tect proteins inside the intestinal tract and facilitate
its transport from the gut lumen to the blood com-
partment has been suggested (Aboubakar et al., 2000;
Michel et al., 1991). Several pre-formulation studies
and in vitro and in vivo assays have been performed to-
wards the optimization of insulin oral delivery systems
(Hari et al., 1996; Marschutz and Bernkop-Schnurch,
2000; Onal and Zihnioglu, 2002; Takenaga et al., 2002),
requiring appropriated and validated methods to assess
truthful profiles of insulin release from delivery systems
as well as its pharmacokinetic behaviour. However, it
has been reported that not only analytical techniques
used for the development of pharmaceuticals must be
INTRODUCTION
Reversed-phase HPLC, a technique used to separate
proteins based on hydrophobicity, is probably the most
used analytical method for separation and determina-
tion of peptides and proteins in an extensive range of
applications (Aguilar, 2004). The method is powerful
and sensitive, being an accurate way to measure insulin
in both artificial and biological environments (Khaksa
et al., 1998; Moslemi et al., 2003; Oliva et al., 2000). Also,
official monographs, namely the US and European
Pharmacopoeia, present HPLC methods for insulin
determination. However, these methods usually require
long run times and use buffers as mobile phases
that are often responsible for contamination of HPLC
systems due to salt precipitations.
Insulin is a protein administered subcutaneously to
humans for the treatment of type I diabetes mellitus
to control glucose homeostasis when pancreatic β-cells
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validated but also techniques for determination of their
quality characteristics (Épshtein, 2004).
In this paper, a new rapid reversed-phase HPLC
method for the determination of insulin from nanopar-
ticulate carriers made from alginate and chitosan is
described and validated. Furthermore, its application to
characterization of an insulin-loaded alginate/chitosan
nanoparticulate system was also evaluated. The specific
application to insulin nanoparticulate dosage forms
would provide a suitable way to characterize both
system carrier and insulin stability after entrapment.
EXPERIMENTAL
Materials. The human insulin reference standard (lot
RS0325, 7.0 mg lyophilized human biosynthetic insulin per
vial) and commercial Humulin Regular® (3.5 mg/mL human
insulin) were kindly supplied by Lilly Farma, Portugal.
Acetonitrile (LiChrosolv HPLC grade) and trifluoroacetic
acid (TFA) were obtained from Merck® (Darmstadt,
Germany). Prior to use, acetonitrile and 0.1% TFA aqueous
solution prepared with deionized water (Milli-Q®, Moslheim,
France) were filtered with a 0.45 µm filter and degassed
for 15 min.
Low G-content sodium alginate (FG = 0.39) and low
molecular weight chitosan (~50 kDa) were purchased from
Aldrich (Oakville, Canada). Calcium chloride was obtained
from Aldrich (Milwaukee, USA).
Equipment. A Varian 9012 Gradient Solvent Delivery
System Varian 9012 and a Varian 9050 Variable Wavelength
UV-VIS Detector (Varian®, USA) were used to perform
all chromatographic runs. The HPLC system was equipped
with an XTerra RP18 column, 5 µm particle size, 4.6 mm
internal diameter × 250 mm length (Waters®, USA) and
a LiChrospher® 100 RP18, 5 µm particle size guard column
(Merck, Germany). Equipment control, data acquisition and
integration were executed with the Star Chromatography
Workstation (Varian®, USA).
Chromatographic conditions. The mobile phase consisted
of acetonitrile and 0.1% TFA aqueous solution initially set in
the ratio 30:70 (v/v), which was linearly changed to 40:60 (v/v)
over 5 min. From 5 to 10 min the ratio 40:60 (v/v) was kept
constant. Eluent was pumped at a flow rate of 1 mL/min, the
injection volume was 20 µL and detection wavelength was
214 nm. All experiments occurred at room temperature and
the total area of peak was used to quantify the insulin.
These conditions were investigated to provide a simple pro-
cedure with the best peak resolution regarding symmetry and
tailing, reduce run time lower the cost of analysis.
Preparation of standard solutions. Calibration curves
for seven human insulin standard solutions were prepared at
concentrations of 1, 3, 6, 12.5, 25, 50 and 100 µg/mL in USP
XXVI acetate buffer pH 4.7. This pH was chosen due to the
pH environments in which the nanoparticulate carriers were
produced and in which the supernatants obtained after
centrifugation were analyzed. A primary stock solution of
700 µg/mL was accurately prepared following by rigorous
dilution with the same buffer solution to give secondary
standard solutions. Humulin Regular® was appropriately
diluted to a final concentration of 35 µg/mL. Freshly prepared
stock solutions were used for all determinations and were
kept at 4°C between each injection.
Validation of the method. The method was validated in
agreement with International Conference on Harmonization
guidelines (ICH, 1996), using the following analytical para-
meters: linearity, precision, accuracy, specificity, detection and
quantitation limits and robustness. Linearity was evaluated by
calculation of a regression line using least squares method.
Calibration curves were obtained from seven different con-
centrations analyzed three times. Precision was assessed by
testing the repeatability of three different standard solutions
10 times in the same day (intra-day) and by intermediate pre-
cision analyzing the same three standard solutions three times
on different days (inter-day). Accuracy was tested by percent-
age recoveries of mean of three determinations of insulin at
three different concentrations precisely prepared and by
determination of the relative standard deviation (RSD).
Specificity was determined by comparing nanoparticulate
carrier samples with and without insulin, the latter being
referred to as empty systems. Detection limit (DL) and
quantitation limit (QL) were determined based on the
standard deviation of the response and on the slope of the
calibration curve, using the following expressions:
  
DL  
.
=
3 3σ
S
  
QL  =
10σ
S
where σ is the standard deviation of the response and S is
the slope of the calibration curve. Robustness was evaluated
according to the application of the method and based on the
variation of the pH of insulin standard solutions.
Application of the method. Nanoparticulate carriers based
on alginate ionotropic pre-gelation with calcium ions followed
by chitosan polycationic complexation were prepared
(Sarmento et al., 2004). For the preparation of insulin-loaded
carriers the protein was mixed with alginate solution prior
to pre-gelation step with calcium ions. Nanoparticles were
isolated by centrifugation (20,000 × g/45 min). Association
efficiency (AE) and loading capacity (LC) of insulin to
nanoparticulate carriers were obtained according to the
following equations:
  
AE
Total amount of insulin  
Free insulin in supernatant
Total amount of insulin
    =
−
× 100
  
LC
Total amount of insulin  
Free insulin in supernatant
Total weight of nanoparticles
    =
−
× 100
These parameters were analyzed in both fresh nanopar-
ticulate carriers and after one month of shelf life. All insulin
determinations were made in triplicate.
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Figure 1. Representative chromatogram of insulin detection.
To establish the insulin release profile from nanoparticles
at simulated gastric and intestinal pH, nanoparticles were
placed into test tubes containing 20 mL of USP XXVI HCl
buffer pH 1.2 (120 min/100 rpm) or USP XXVI phosphate
buffer pH 6.8 (120 min/100 rpm). At appropriate intervals
aliquots of 100 µL were taken and replaced by fresh medium.
Aliquots were centrifuged at 5000 g for 15 min to eliminate
possible insoluble polyions and the amount of insulin released
from the nanoparticles was evaluated by HPLC as described
above.
RESULTS AND DISCUSSION
Optimization of the chromatographic method
An optimized reversed-phase HPLC method for
the assessment of human insulin associated with
nanoparticulate carriers has been proposed. Previous
experiences were exploited to provide a simple pro-
cedure with the best chromatographic peak resolu-
tion, reduced run time and low cost of analysis. All
these factors contribute to the establishment of an
analytical method which permits the analysis of a large
series of samples and avoiding possible degradation
due long analysis time. A typical chromatogram for the
proposed method is depicted in Fig. 1. The relatively
symmetrical insulin peak has a retention time of
5.614 min.
Additionally, no peak from possible degradation
products, as mentioned in other investigations (Oliva
et al., 2000), was observed in the chromatograms, show-
ing the purity of insulin used and its stability in stock
solutions. Nevertheless, degradation products of insulin
could be promoted by heating and agitation. These pro-
cedures were not carried out for standard solutions
used in the validation of this method.
Method validation
Linearity. Calibration curves for seven human insulin
standard solutions of different concentrations ranging
from 1 to 100 µg/mL at concentrations of 1, 3, 6, 12.5,
25, 50 and 100 µg/mL were prepared in USP XXVI
acetate buffer pH 4.7. A primary stock solution was
accurately prepared followed by rigorous dilution to
give secondary standard solutions. Each sample was
analyzed three times. A good linearity was obtained in
the range of study (Fig. 2). The calibration curve and
regression coefficient were:
area = 6652 (±89)C + 4799 (±3455)
correlation coefficient (R2) = 0.9996 (n = 21).
The R2 obtained was higher than 0.999, as frequently
recommended (Épshtein, 2004), indicating a good
linearity in the proposed range.
Precision. Precision of the assay was determined by
analyzing the samples at three different concentrations.
For the assessment of the intra-day variation samples
were analyzed in triplicate (n = 3) in three different
Figure 2. Calibration curve obtained with insulin standard
solutions using the proposed HPLC method (n = 21).
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days; for the inter-day variation they were analyzed 10
times (n = 10) in the same day. As depicted in Table 1
the intra-day relative standard deviation ranged from
2.21 to 3.80, 0.87 to 1.62 and 0.18 to 0.45 at 12.5, 50
and 100 µg/mL, respectively. Inter-day RSD was 2.55,
1.42 and 0.25, for the same concentrations of standard
solutions. These results indicate good precision of the
analytical method (Bressolle et al., 1997).
Accuracy. The accuracy characterizes the proximity
between the obtained experimental results and the real
results, and was assessed by the determination of the
percentage recovery of a known amount of insulin.
Three different standard solutions of 7, 28 and 50 µg/
mL were precisely prepared as described above,
analyzed, and a mean recovery of 100.02% ± 1.04%
was found. To investigate accuracy using another
source of insulin, a commercial formulation of insulin,
Humulin Regular® was diluted 1:100 in order to obtain
a final concentration of 35 µg/mL (within the studied
range). A mean recovery of 100.37% ± 0.65% was
found. These results show the agreement between the
obtained experimental values and theorical ones. Thus,
it can be emphasized that this method is accurate.
Table 2 summaries obtained recoveries from differ-
ent standard solutions, in comparison to a commercial
formulation.
Specificity. Specificity of method was verified by
analyzing potential interfering peaks of the formulation
components at insulin retention time. Pure aqueous
solutions of polyelectrolytes (alginate and chitosan)
were prepared at the same concentrations used for
nanoparticulate production. In addition, empty nano-
particles, i.e. consisting only of alginate and chitosan,
were also prepared and further centrifuged to obtain
the supernatant. Three injections of each solutions, i.e.
alginate solutions, chitosan solution and supernatant,
were performed in same conditions as previously de-
scribed for insulin detection. The main purpose was
to detect any retention peak due to any isolate polymer
or combination of them. No interfering peaks were ob-
served. Therefore, this method was found to be specific.
Detection Limit (DL) and Quantitation Limit (QL).
The DL can be defined as the lowest concentration
of analyzed substance in a certain sample that can be
detected under certain conditions by a given method.
QL is the lowest concentration that can be determined
at an acceptable precision and accuracy. These defini-
tions were first introduced by ICH and nowadays are
generally accepted. Several alternatives are described to
determine DL and QL (Épshtein, 2004). In the present
work, these parameters were established from the SD
of the response and the slope of the calibration curve.
Values of SD were calculated from standard deviation
of the free terms taken from regression equations of
calibration curves obtained using reference samples in
the region of LD. LD and QL were found to be 0.24
and 0.72 µg/mL, respectively. These values are slightly
lower than those found in previous studies (Kunkel
et al., 1997; Moslemi et al., 2003; Oliva et al., 2000),
which can be pointed as an advantage compared with
other methods.
Robustness. The evaluation of robustness was based
on the recovery and RSD values obtained using insulin
standard solutions of different pH (Table 3). This
approach has the advantage of prediction of the
application of the method not only for small varia-
tions of pH during the production of nanoparticu-
late, but also for insulin release at simulated gastric
and intestinal conditions. Insulin solutions (50 µg/mL)
Table 1. Results of precision tests for the determination of
insulin in standard solutions
Standard
solution Measured SD RSD
(µg/mL) Day (µg/mL) (%) (%)
Intra-day variation (n = 3)
12.5 0 13.09 0.29 2.21
5 12.56 0.44 3.48
10 12.76 0.49 3.80
50 0 51.06 0.45 0.87
5 50.71 0.82 1.62
10 50.51 0.70 1.39
100 0 99.74 0.36 0.36
5 100.03 0.18 0.18
10 99.96 0.44 0.45
Inter-day variation (n = 10)
12.5 12.95 0.33 2.55
50 50.99 0.72 1.42
100 99.90 0.24 0.25
Table 2. Results of recovery (%) and RSD (%) for insulin
from standard solutions (n = 3)
Standard solution (µg/mL) Recovery (%) RSD (%)
7 98.86 2.75
28 100.88 0.77
50 100.30 0.63
35 (Diluted Humulin®) 100.37 0.65
Table 3. Robustness of proposed method in terms of recovery
(%) and RSD (%) for 7 µg/ml insulin standard solutions at
different pH (n = 3)
pH of insulin
standard solution Recovery (%) RSD (%)
1.2 99.71 1.17
4.7 98.86 2.75
6.8 100.14 2.07
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prepared with pH 1.2, 4.7 and 6.8 buffers were tested
and values were evaluated in terms of recovery (%)
and RSD. The low values of RSD (1.17, 2.75 and 2.07)
and high values of recovery (99.71, 98.86 and 100.14%)
indicate that this analytical procedure is robust with re-
spect to sample pH and allows its use for further insulin
determinations from same nanoparticulate systems.
Application of the method. The proposed method
was applied to study insulin association with nanopar-
ticulate carriers produced by ionotropic pre-gelation
of calcium ions and alginate reinforced with chitosan
polycation. The carriers were prepared in an aqueous
environment and further centrifuged for their isolation
in order to determine indirectly insulin association effi-
ciency that remained in the supernatant after formation
of nanoparticulate carriers. Previous experiments were
done to establish the ideal formulation and to charac-
terize those nanoparticulates. An insulin AE of 69.30
± 3.80 (%) and a LC of 11.17 ± 0.61 (%) were found
(n = 3), which are highly accurate results as compared
with the colorimetric method (Sarmento et al., 2005).
No insulin degradation peak was detected. The AE was
also evaluated during the shelf life in order to assess
the protein stability associated with the carriers. After
one month of storage at 4°C the AE decreased to
58.70 ± 5.79. It was demonstrated that none of other
nanoparticle components interfered with insulin deter-
mination, but a centrifugation step was required to pro-
tect the HPLC column from contamination and delay
pre-column obstruction.
The representative insulin release–time profile from
nanoparticles in gastric and intestinal pH simulated
conditions is illustrated in Fig. 3, as a suitable applica-
tion of this method. Insulin release was characterized
by an immediate burst effect, in both media. Up to
50% of insulin was released from nanoparticles within
5 min of contact with both acidic and intestinal environ-
ments and a cumulative release of 75% occurred after
2 h. These results seem to indicate that a significant
amount of insulin initially associated with nanoparticles
remained on their surfaces by weak linkages to
polymers and alginate nucleus did not have the neces-
sary strength to entrap all protein. Also, a considerable
fraction of insulin, 30%, can conserve a stable inter-
action with nanoparticles after being placed in contact
with both aqueous simulated gastric and intestinal re-
lease medium for 2 h. After 2 h of assay, no detectable
hydrolysis degradation products of insulin and only
a well-defined peak appeared on the chromatogram,
indicating that nanoparticulate carrier could retain
insulin primary structure during encapsulation. Partial
protection against insulin release can be attributed to
the alginate-calcium ions network that pre-gel can
provide against insulin diffusion (Coppi et al., 2002;
Vandenberg and De La Noue, 2001).
CONCLUSION
This study has described a new, rapid and validated
RP-HPLC method for insulin determination according
ICH guidelines. All parameters are within the limits
proposed by those guidelines for pharmaceutical formu-
lations, indicating that this method is specific, precise,
accurate and robust with low detection and quantifica-
tion limits. Furthermore, suitable application for insulin
in vitro analysis can be assumed during formulation de-
velopment and characterization. The proposed method
was used to predict the association efficiency and the
release profile of insulin from nanoparticulate carriers
composed of contrary charged polysaccharides. Insulin
entrapment is essentially by reversible ionic inter-
actions, which permits an absence of interaction of
polymers on protein determination in the different
steps of formulation development.
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